Additionally, the role of consistent monitoring and patient education on IOP management strategies will be pivotal in ensuring that the benefits of anti-VEGF therapies outweigh the risks associated with potential ocular hypertension [10,20]. This evidence concerns the gene VEGFA and ocular hypertension.